Leveraging the genetic correlation between cumulus cells and egg quality, GemaSM has two products, GemARTviaSM and GemART23SM , well into commercial development and a third in discovery.
GemART tests will be offered through a CLIA-registered reference laboratory.
During IVF, cumulus cells are routinely removed from mature eggs and discarded. For GemART testing, rather than discard them, technicians at fertility clinics will simply extract cumulus cell mRNA using off the shelf lab supplies Gema provides. The samples will then be shipped to Gema's central reference lab where the cumulus cell mRNA will be compared to an expression profile of proprietary genetic markers. Once analyzed, Gema will provide clinicians with a report scoring each egg individually prior to embryo implantation.
For patients, GemART could dramatically improve IVF outcomes by:
- Increasing the probability of a healthy pregnancy and viable birth
- Reducing chance of multiple births
- Lowering the costs in treatments and hospital stays
- Reducing physical and emotional burdens on mothers undergoing infertility treatment
For clinicians, GemART may offer:
- Improved patient satisfaction
- Competitive advantage over other fertility clinics
- Greater confidence in single embryo transfer (SET)
- Greater confidence in day 2 or day 3 embryo transfer